Designs of drug-combination phase I trials in oncology: A systematic review of the literature

Annals of Oncology

Volumn 26, Issue 4, 2015, Pages 669-674

  Riviere, Marie Karelle ^a,b   Le Tourneau, C ^c,d   Paoletti, X ^c   Dubois, F ^b   Zohar, S ^a  

^a INSERM   (France)

^b IRIS Institut de Recherches Internationales Servier   (France)

^c INSERM U900   (France)

^d INSTITUT CURIE   (France)

Author keywords

Dose finding; Drug combinations; Phase i trials

Indexed keywords

ANTINEOPLASTIC AGENT; CYTOTOXIC AGENT;

BIBLIOMETRICS; DOSE CALCULATION; DRUG DOSE ESCALATION; DRUG SAFETY; HUMAN; INFORMATION RETRIEVAL; ONCOLOGY; PHASE 1 CLINICAL TRIAL (TOPIC); PRACTICE GUIDELINE; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; REFERENCE DATABASE; REVIEW; SYSTEMATIC REVIEW (TOPIC); DRUG DESIGN; META ANALYSIS; NEOPLASMS; PROGNOSIS;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS, PHASE I AS TOPIC; DRUG DESIGN; HUMANS; MEDICAL ONCOLOGY; NEOPLASMS; PROGNOSIS;

EID: 84926453341     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdu516     Document Type: Review

References (34)

1. Storer BE. Design and analysis of phase I clinical trials. Biometrics 1989; 45: 925-937.
2. Cheung YK. Dose Finding by the Continual Reassessment Method. New York: Chapman & Hall/CRC 2011.
3. Le Tourneau C, Lee JJ, Siu LL. Dose escalation methods in phase I cancer clinical trials. J Natl Cancer Inst 2009; 101: 708-720.
4. Curigliano G, Spitaleri G, Magni E et al. Cisplatin, etoposide and continuous infusion bleomycin in patients with testicular germ cell tumors: efficacy and toxicity data from a retrospective study. J Chemother 2009; 21(6): 687-692.
5. Bamias A, Aravantinos G, Kastriotis I et al. Report of the long-term efficacy of two cycles of adjuvant bleomycin/etoposide/cisplatin in patients with stage I testicular nonseminomatous germ-cell tumors (NSGCT): a risk adapted protocol of the Hellenic Cooperative Oncology Group. Urol Oncol 2011; 29(2): 189-193.
6. Slamon DJ, Leyland-Jones B, Shak S et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001; 344(11): 783-792.
7. Flaherty KT, Infante JR, Daud A et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med 2012; 367(18): 1694-1703.
8. Soria JC, Massard C, Izzedine H. From theoretical synergy to clinical supraadditive toxicity. J Clin Oncol 2009; 27: 1359-1361.
9. Mandrekar SJ. Dose-finding trial designs for combination therapies in oncology. J Clin Oncol 2014; 32: 65-67.
10. Adjei AA. What is the right dose? The elusive optimal biologic dose in phase I clinical trials. J Clin Oncol 2006; 24(25): 4054-4055.
11. Cannistra SA. Challenges and pitfalls of combining targeted agents in phase I studies. J Clin Oncol 2008; 26(22): 3665-3667.
12. Hamberg P, Ratain MJ, Lesaffre E, Verweij J. Dose-escalation models for combination phase I trials in oncology. Eur J Cancer 2010; 46(16): 2870-2878.
13. Harrington JA, Wheeler GM, Sweeting MJ et al. Adaptive designs for dualagent phase I dose-escalation studies. Nat Rev Clin Oncol 2013; 10(5): 277-288.
14. Jain RK, Lee JJ, Hong D et al. Phase I oncology studies: evidence that in the era of targeted therapies patients on lower doses do not fare worse. Clin Cancer Res 2010; 16(4): 1289-1297.
15. LoRusso PM, Boerner SA, Seymour L. An overview of the optimal planning, design, and conduct of phase I studies of new therapeutics. Clin Cancer Res 2010; 16(6): 1710-1718.
16. Booth CM, Calvert AH, Giaccone G et al. Endpoints and other considerations in phase I studies of targeted anticancer therapy: recommendations from the task force on Methodology for the Development of Innovative Cancer Therapies (MDICT). Eur J Cancer 2008; 44(1): 19-24.
17. Seymour LK, Calvert AH, Lobbezoo MW et al. Design and conduct of early clinical studies of two or more targeted anticancer therapies: recommendations from the task force on Methodology for the Development of Innovative Cancer Therapies. Eur J Cancer 2013; 49(8): 1808-1814.
18. U.S. Department of Health, Human Services, F., Drug Administration, C. f. B. E., and Research. Guidance for Industry, Clinical Considerations for Therapeutic Cancer Vaccines. 3 December 2014, http://www.fda.gov/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/Xenotransplantation/default.htm (11 December 2014, date last accessed).
19. Le Tourneau C, Gan HK, Razak AR, Paoletti X. Efficiency of new dose escalation designs in dose-finding phase I trials of molecularly targeted agents. PLoS One 2012; 7(12): e51039.
20. Thall PF, Cook JD. Dose-finding based on efficacy-toxicity trade-offs. Biometrics 2004; 60(3): 684-693.
21. Doussau A, Thiebaut R, Paoletti X. Dose-finding design using mixed-effect proportional odds model for longitudinal graded toxicity data in phase I oncology clinical trials. Stat Med 2013; 32 (30): 5430-5447.
22. Zhang W, Sargent DJ, Mandrekar S. An adaptive dose-finding design incorporating both toxicity and efficacy. Stat Med 2006; 25: 2365-2383.
23. Huang X, Biswas S, Oki Y et al. A parallel phase I/II clinical trial design for combination therapies. Biometrics 2007; 63: 429-436.
24. Wang K, Ivanova A. Two-dimensional dose finding in discrete dose space. Biometrics 2005; 61: 217-222.
25. Mandrekar SJ, Cui Y, Sargent DJ. An adaptive phase I design for identifying a biologically optimal dose for dual agent drug combinations. Stat Med 2007; 26: 2317-2330.
26. Mandrekar SJ, Qin R, Sargent DJ. Model-based phase I designs incorporating toxicity and efficacy for single and dual agent drug combinations: methods and challenges. Stat Med 2010; 29: 1077-1083.
27. Yin G, Yuan Y. A latent contingency table approach to dose finding for combinations of two agents. Biometrics 2009; 65: 866-875.
28. Yin G, Yuan Y. Bayesian dose finding in oncology for drug combinations by copula regression. Appl Stat JRSS 2009; 58: 211-224.
29. Thall PF, Millikan RE, Mueller P, Lee SJ. Dose-finding with two agents in phase I oncology trials. Biometrics 2003; 59: 487-496.
30. Riviere MK, Dubois F, Zohar S. Competing designs for drug combination in phase I dose-finding clinical trials. Stat Med 2014 January 27 [epub ahead of print], doi:10.1002/sim.6094.
31. Ivanova A, Wang K. A non-parametric approach to the design and analysis of twodimensional dose-finding trials. Stat Med 2004; 23: 1861-1870.
32. Gandhi L, Bahleda R, Tolaney SM et al. Phase I study of neratinib in combination with temsirolimus in patients with human epidermal growth factor receptor 2-dependent and other solid tumors. J Clin Oncol 2014; 32: 68-75.
33. Conaway MR, Dunbar S, Peddada SD. Designs for single- or multiple-agent phase I trials. Biometrics 2004; 60: 661-669.
34. Jones DR, Moskaluk CA, Gillenwater HH et al. Phase I trial of induction histone deacetylase and proteasome inhibition followed by surgery in non-small-cell lung cancer. J Thorac Oncol 2012; 11: 1683-1690.